Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. The Consensus Interferon Study Group.
about
Interferon for interferon nonresponding and relapsing patients with chronic hepatitis CAntiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinaseFour-week pegylated interferon a-2a monotherapy for chronic hepatitis C with genotype 2 and low viral load: A pilot, randomized studyManaging chronic hepatitis C in the difficult-to-treat patientBenefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapyMethodological issues in papers on IFN therapy: time for reappraisal.Antiretroviral therapy, interferon sensitivity, and virologic setpoint in human immunodeficiency virus/hepatitis C virus coinfected patientsViral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection.Effects of immunosuppression and organ transplantation on the natural history and immunopathogenesis of hepatitis C virus infection.Peginterferon and ribavirin treatment for hepatitis C virus infectionStrengths and limitations of commercial tests for hepatitis C virus RNA quantificationNanomedicines in the treatment of patients with hepatitis C co-infected with HIV--focus on pegylated interferon-alpha.Inhibition of internal ribosomal entry site-directed translation of HCV by recombinant IFN-alpha correlates with a reduced La protein.Predictive value of early HCV RNA quantitation for sustained response in nonresponders receiving daily interferon and ribavirin therapy.Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study.2'-,5'-Oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C.Early detection of nonresponse to interferon plus ribavirin combination treatment of chronic hepatitis C.Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C.First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline.Interferon-alpha plus ribavirin for 12 months increases the sustained response rates in chronic hepatitis C relapsers.Changes in hepatitis C viral load during first 14 days can predict the undetectable time point of serum viral load by pegylated interferon and ribavirin therapy.A randomized trial of high-dose interferon alpha-2b, with or without ribavirin, in chronic hepatitis C patients who have not responded to standard dose interferon.Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial.
P2860
Q24201588-06A1A104-273E-4AD1-BFEA-9729458316C3Q27469720-7189557D-848C-4DAA-8E2D-C1F0C0C0FF05Q27490396-3ECA31AA-860A-499F-BBF7-A7AEB169F37CQ27490409-4F08309A-147E-4517-9BBA-7DBC3A741E6EQ33592250-A2D798D6-19B7-4EE9-884B-EA7CF6D2932DQ33940500-2C7D0A1D-0E8B-4B28-BD73-DD4C73ACDDFDQ33946635-93E867BC-7704-4414-8200-5FDA6BA13EF6Q34129547-0E3048EA-4483-4BF6-A548-ECC27B85AD20Q34294938-60628957-CB16-4784-B341-D4ECE6BD42F3Q34521371-B3A67DBA-2541-4012-B5F0-9FE22B85BD04Q35551304-0B740A24-69B6-4A14-A729-00D8FBD03AD1Q36920320-22DF82BD-FEFB-4093-BAC0-771C7748E379Q40757675-405FD101-67C3-492E-B40F-1519D10DB234Q42981457-8C231DE8-CB2E-4C55-8787-FD1E4992C253Q42989003-BC96A551-8244-4C71-998A-574E32CED157Q43031195-889DE0A8-A33D-4F80-AC2C-4F51DAE2B25BQ43037854-04E6FEC7-01A1-4AFB-A103-DBB0B5E6EFE2Q43039938-F0441F46-B559-406A-9B51-8C57D2A8410DQ43039947-82733483-AF93-444A-B41C-E2A2DD06CC34Q43892504-437921BC-55EF-4B00-803B-1B0B9314F84AQ50544983-85D32D84-0558-4D3D-A615-5F5ED71EFC4CQ50584912-AB058775-5260-49FB-BFE6-026142DDDADAQ50585032-9798681B-6BC1-45EB-A3C9-7906D1CD72D5
P2860
Early hepatitis C virus-RNA responses predict interferon treatment outcomes in chronic hepatitis C. The Consensus Interferon Study Group.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Early hepatitis C virus-RNA re ...... sensus Interferon Study Group.
@en
Early hepatitis C virus-RNA re ...... sensus Interferon Study Group.
@nl
type
label
Early hepatitis C virus-RNA re ...... sensus Interferon Study Group.
@en
Early hepatitis C virus-RNA re ...... sensus Interferon Study Group.
@nl
prefLabel
Early hepatitis C virus-RNA re ...... sensus Interferon Study Group.
@en
Early hepatitis C virus-RNA re ...... sensus Interferon Study Group.
@nl
P2093
P356
P1433
P1476
Early hepatitis C virus-RNA re ...... sensus Interferon Study Group.
@en
P2093
D J van Leeuwen
F B Hollinger
K D Mullen
N Pimstone
P304
P356
10.1002/HEP.510280533
P407
P577
1998-11-01T00:00:00Z